Digital delivery of personalized cancer risk reduction: Real-world engagement with ACS CancerRisk360.

Abstract

e22515 Background: Access to personalized, disease site agnostic guidance to lower cancer risk remains an unmet public health need. In response, the American Cancer Society (ACS) launched ACS CancerRisk360, a large scale publicly available dissemination tool designed to assess risk and connect users to evidence-based recommendations to reduce modifiable risks. This free web-based app uses a sophisticated decision matrix to synthesize clinical variables, family history, lifestyle factors, and evidence-based guidelines into personalized risk reduction and screening recommendations for the user. Methods: ACS CancerRisk360 was developed with input from diverse clinical specialists, patients, and caregivers, and reflects established health literacy best practices. To maximize usability and minimize data loss risk, ACS CancerRisk360 incorporates read-aloud functionality and retains only aggregate, nonidentifiable demographic information. Personal health information is not stored, but engagement metrics are captured using Matomo and Microsoft Power BI. This analysis summarizes platform utilization, engagement, and feedback from January–December 2025. Results: 161,278 page views generated 89,909 assessment starts and 71,194 completed assessments (79% completion rate). Most users were aged 30–69 years (72%); 78% were female; 83.5% of users identified their race or ethnicity as White. ZIP-code–level data demonstrated nationwide reach with users from 50 states, Puerto Rico and Guam. Users spent an average of 14 minutes engaged with the tool. Engagement with personalized outputs was high: 7719 users downloaded, 7680 emailed, 2122 printed, and 1173 texted their results to a mobile phone. Users made 17,892 visits to additional ACS educational resources. The most frequently accessed linked resources addressed body weight and cancer risk (1301 visits), radon and lung cancer (1005 visits), and genetic testing for cancer risk (978 visits). 6899 users rated the tool 4.24 of 5. Free text comments from 1162 users demonstrated high user satisfaction, particularly with screening recommendations, diet and activity guidance, and information about genetic testing. The most commonly cited limitation was the absence of a numeric risk score. Conclusions: ACS CancerRisk360 demonstrates the feasibility and impact of a large-scale, direct-to-consumer digital platform for delivery of personalized, evidence-based cancer risk-reduction guidance. High completion rates, sustained engagement with personalized outputs, and positive user feedback suggests the tool effectively supports awareness of cancer risk, screening needs, implications of family history, and modifiable lifestyle behaviors. Future development will focus on enhancing personalization, leveraging emerging scientific evidence, and expanding dissemination to reach more diverse populations and underserved communities.